Early Pseudomonas aeruginosa infection in individuals with cystic fibrosis: is susceptibility testing justified? | Zendy

Daniel W. MacDonald | Zendy; Leah Cuthbertson | Zendy; C. Doherty | Zendy; S. Campana | Zendy; N. Ravenni | Zendy; Giovanni Taccetti | Zendy; John R. W. Govan | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Early Pseudomonas aeruginosa infection in individuals with cystic fibrosis: is susceptibility testing justified?

Author(s) -

Daniel W. MacDonald,

Leah Cuthbertson,

C. Doherty,

S. Campana,

N. Ravenni,

Giovanni Taccetti,

John R. W. Govan

Publication year - 2010

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkq342

Subject(s) - tobramycin , pseudomonas aeruginosa , amikacin , colistin , cystic fibrosis , microbiology and biotechnology , population , antibiotics , meropenem , ciprofloxacin , etest , ceftazidime , medicine , biology , antibiotic resistance , gentamicin , bacteria , genetics , environmental health

To test the presumption that Pseudomonas aeruginosa isolates responsible for initial lung infection in individuals with cystic fibrosis (CF) are invariably susceptible to antipseudomonal agents.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research